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Abstract 
Background: Carbon nanoparticles show significant lymphatic tropism and can be used to identify lymph nodes 
surrounding mid‑low rectal tumors. In this study, we analyzed the effect of trans anal injection of a carbon nanoparti‑
cle suspension on the outcomes of patients with mid‑low rectal cancer who underwent laparoscopic resection.
Methods: We collected the data of 87 patients with mid‑low rectal cancer who underwent laparoscopic resection 
between November 2014 and March 2015 at Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union 
Medical College. For 35 patients in the experimental group, the carbon nanoparticle suspension was injected transan‑
ally into the submucosa of the rectum around the tumor 30 min before the operation; 52 patients in the control 
group underwent the operation directly without the injection of carbon nanoparticle suspension. We then compared 
the operation outcomes between the two groups.
Results: In the experimental group, the rate of incomplete mesorectal excision was lower than that in the control 
group, but no significant difference was found (2.9% vs. 7.7%, P = 0.342). The distance between the tumor and the 
circumferential resection margin was 5.8 ± 1.4 mm in the experimental group and 4.8 ± 1.1 mm in the control group 
(P = 0.001). The mean number of lymph nodes removed was 28.2 ± 9.4 in the experimental group and 22.7 ± 7.3 
in the control group (P = 0.003); the mean number of lymph nodes smaller than 5 mm in diameter was 10.1 ± 7.5 
and 4.5 ± 3.7, respectively (P < 0.001). Three patients in the experimental group received lateral lymph node resec‑
tion. Among the three patients, we retrieved three nodes (one stained node) from the first patient, three nodes (two 
stained nodes) from the second patient, and two nodes (no stained nodes) from the third patient.
Conclusions: Injecting a carbon nanoparticle suspension improved the outcomes of patients who underwent 
laparoscopic resection for mid‑low rectal cancer; it also improved the accuracy of pathologic staging. Moreover, for 
selected patients, this technique narrowed the scope of lateral lymph node dissection.
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Background
Colorectal cancer is one of the leading causes of death 
in China, and owing to people’s lifestyle changes its 
incidence in China is increasing [1, 2]. For most patients 
with resectable rectal cancers (stages I, II, and partial 
III), surgical operation offers the best potential for cure 
and long-term survival. Several factors, such as the sta-
tus of the circumferential resection margin (CRM), the 
completeness of the mesorectum, and the number of 
lymph nodes retrieved, have been shown to be prog-
nostic factors of rectal cancer [3–6], whereas the effect 
of lateral lymph node dissection on prognosis has not 
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been determined [7–10]. Since 1988, Yoshida et al. [11] 
have reported that carbon nanoparticles, which are use-
ful, non-toxic, lymphatic tracers, have high lymphatic 
tropism and can reside for long periods of time in the 
lymph nodes. Submucosal injection of a carbon nano-
particle suspension around the tumor may be associated 
with operation outcomes and rectal cancer progno-
sis [12]. Between November 2014 and March 2015, for 
selected patients with mid-low rectal cancer, we per-
formed submucous injections of carbon nanoparticle 
suspensions immediately prior to laparoscopic resec-
tion. We then evaluated the effect of the injection on the 




Between November 2014 and March 2015, 87 mid-low 
rectal cancer patients underwent laparoscopic resection 
at Cancer Hospital, Chinese Academy of Medical Sci-
ences & Peking Union Medical College. For all patients, 
definite diagnosis was made by colonoscopy with biopsy 
before the operation. Routine preoperative evaluation 
included physical examination, abdominal computed 
tomography scan, abdominal ultrasound, and barium 
enema. Patients who had received neoadjuvant therapy 
were excluded from this study.
Of the 87 patients, 35 received transanal injection of 
carbon nanoparticle suspensions before the operation 
and were assigned to the experimental group; the remain-
ing 52 patients who did not receive transanal injection 
of carbon nanoparticle suspensions were assigned to 
the control group. Whether a patient received transa-
nal injection of a carbon nanoparticle suspension prior 
to the operation was based exclusively on the patient’s 
individual decision after providing informed consent 
detailing the method and risks. Thirty-two patients in 
the experimental group and all 52 patients in the con-
trol group underwent traditional laparoscopic-assisted 
resection. For three patients in the experimental group, 
swollen lymph nodes close to the internal iliac vessels 
were detected by abdominal computed tomography 
scan. These three patients with clinical pathologic stage 
cT3N  +  M0 disease refused neoadjuvant therapy and 
underwent laparoscopic rectal cancer resection with lat-
eral lymph node dissection.
For patients in both groups, we recorded the com-
pleteness of the mesorectum excision, the rate of posi-
tive CRM, the distance between the tumor and the CRM, 
the number of lymph nodes removed, and the number of 
lymph nodes smaller than 5  mm in diameter and com-
pared the results.
Surgical procedure
All patients underwent routine bowel preparation prior 
to surgery. After general anesthesia was administered, 
all patients in the experimental group then underwent 
disinfection of the rectal lumen. Next, 5  mL of carbon 
nanoparticle suspension were injected transanally to 
the submucosa of the rectum around the tumor 30 min 
before the operation. All operations were performed by 
the same experienced surgeons using the laparoscopy-
assisted technique, following the radical resection prin-
ciple. Ligation of the inferior mesenteric artery pedicle, 
dissociation of the intestinal canal, separation of the 
sacrum anterior, and dissection of the lymph nodes were 
completed laparoscopically. Transection of the rectum 
was performed through a small abdominal incision. The 
tissues were then removed, and the bowel was prepared 
for anastomosis.
Patients who underwent abdominoperineal resection 
did not receive an abdominal incision. All procedures, 
including closure of the pelvic peritoneum, were com-
pleted laparoscopically, and tissues were removed via the 
perineal incision.
For patients in the experimental group, the periphery 
of staining tissues within the tumor was the demarcation 
line when separating the sacrum anterior, and the stained 
region was protected from damage. The lymph nodes 
were identified by three experienced pathologists.
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware, version 16.0 (IBM, Chicago, IL, USA). P values less 
than 0.05 were considered statistically significant. Cat-
egorical variables were analyzed by the Chi-square test; 




Patients in the two groups were well matched in terms of 
demographic data, including age, sex, body mass index, 
American Society of Anesthesiologists physical sta-
tus score, concomitant diseases, tumor size, distance of 
tumor from the anal verge, and operation type (Table 1).
Pathologic results
The rate of incomplete mesorectal excision in the experi-
mental group was lower than that in the control group 
(2.9% vs. 7.7%), although no significant difference was 
found (P  =  0.342). There were no cases with positive 
CRM in the two groups. The distance between the tumor 
and the CRM was 5.8  ±  1.4  mm in the experimental 
group (median, 6.5 mm) and 4.8 ± 1.1 mm in the control 
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group (median, 4.0 mm); the difference between the two 
groups was significant (P = 0.001).
The mean number of lymph nodes removed from 
patients in the experimental group was 28.2  ±  9.4 
(median, 27), which was more than that from patients in 
the control group (22.7 ±  7.3; median, 22) (P =  0.003). 
The mean number of lymph nodes smaller than 5  mm 
in diameter was 10.1  ±  7.5 (median, 10) in the experi-
mental group and 4.5  ±  3.7 (median, 4) in the control 
group, with a significant difference (P < 0.001) (Table 2). 
Three patients in the experimental group underwent rec-
tal resection with lateral lymph node dissection; a total 
of eight lymph nodes (3, 3, and 2, respectively, from the 
first, second, and third patients) close to the internal iliac 
vessels were removed, including three lymph nodes (1, 
2, and 0, respectively) that were stained by carbon nano-
particles (Figs.  1, 2). Of the eight lymph nodes close to 
the internal iliac vessels, cancer cells were found in two 
lymph nodes (0, 1, and 1, respectively)..
Others
No patients in the experimental group experienced 
adverse effects from the injection of the carbon nanopar-
ticle suspension. For patients with mid-low rectal cancer, 
Submucosal injection of carbon nanoparticle suspen-
sions around the tumor prior to laparoscopic resection 
improved the outcomes of the operation and made the 
pathologic staging more accurate.
Discussion
Total mesorectal excision (TME) is the “gold standard” of 
surgical treatment of rectal cancer [13]. The widespread 
use of TME has caused the local recurrence rate of rec-
tal cancer to decrease considerably [14]. Completeness of 
the mesorectum is a necessary component of TME. We 
found that the technique of injecting carbon nanoparticle 
suspensions might help surgeons identify the anatomi-
cal spaces during laparoscopic resection procedures. The 
Table 1 Comparison of  clinicopathologic characteristics 
in two groups of patients with mid-low rectal cancer
Tumor size is the largest diameter under macroscopic examination
BMI body mass index, ASA American society of anesthesiologists
a  These values are presented as mean ± standard deviation; other values are 







 Men 16 24
 Women 19 28
Age (years)a 60.0 ± 10.7 58.9 ± 9.4 0.631
BMI (kg/m2)a 23.6 ± 2.9 23.2 ± 2.8 0.505
ASA score 0.448
 I 4 3
 II 28 41
 III 3 8
Concomitant diseases 0.948
 Yes 11 16
 No 24 36
Tumor size (cm)a 4.9 ± 2.0 4.6 ± 2.3 0.619
Distance from anal verge 
(cm)a
5.6 ± 1.9 5.3 ± 1.7 0.549
Operation type (cases) 0.459





 I 3 4
 II 6 11
 III 26 37
Tumor differentiation 0.602
 Well 2 1
 Moderate 29 46
 Poor 4 5
Pathologic type 0.721
 Adenocarcinoma 33 48
 Mucinous adenocarcinoma 2 4
Table 2 Comparison of oncologic outcomes in the two groups of patients with mid-low rectal cancer
LN lymph node, CRM circumferential resection margin
a  Values are presented as median (mean ± standard deviation)
Outcome Experimental group (n = 35) Control group (n = 52) P value
Number of removed LNsa 27 (28.2 ± 9.4) 22 (22.7 ± 7.3) 0.003
Number of LNs with diameter <5 mma 10 (10.1 ± 7.5) 5 (4.5 ± 3.7) <0.001
Completeness of mesorectum (cases) 0.342
 Yes 34 48
 No 1 4
Distance between tumor and the CRM (mm)a 6.5 (5.8 ± 1.4) 4.0 (4.8 ± 1.1) 0.001
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interface can be identified about 30 min after the injec-
tion of carbon nanoparticle suspensions; the stained 
periphery is the demarcation line. The sacrum anterior 
can be separated through the tissue space. We found 
that the rate of incomplete mesorectum was reduced due 
to the implementation of this technique, although the 
results were not significant.
Lymph node involvement is an important prognostic 
factor for colorectal cancer patients before distant metas-
tasis occurs. Fewer lymph nodes removed may result in 
worse outcomes for patients with node-positive colorec-
tal cancer because they are more likely to be misclassified 
as node-negative. Kotake et al. [5] found a positive asso-
ciation between the number of removed lymph nodes 
and the number of metastatic lymph nodes. The accu-
racy rate of postoperative pathologic analysis might be 
improved when more lymph nodes are removed. In our 
study, more lymph nodes were removed from patients in 
the experimental group than from patients in the control 
group, and the difference was greater for lymph nodes 
with a diameter less than 5  mm compared with lymph 
nodes with a diameter more than 5 mm. Pathologists may 
be able to identify more lymph nodes when the nodes are 
stained by carbon nanoparticle suspensions.
No consensus exists as yet on lateral lymph node dissec-
tion for rectal cancer [15]. A study by Fujita et al. [10] showed 
that rectal resection with lateral lymph node dissection 
had the disadvantages of longer operation time and greater 
blood loss, but its benefit to the patient’s prognosis was not 
improved compared with that of rectal resection alone. 
However, Park et al. [15] concluded that laparoscopic TME 
with lateral lymph node dissection was “safe and feasible.” 
Further study is needed to determine the safety and efficacy 
of lateral lymph node dissection. Based on the improvements 
in adjuvant therapy, neoadjuvant therapy may be the best 
treatment for rectal cancer with suspected metastasis to the 
lateral lymph nodes. Mid-low rectal cancer patients with sus-
pected metastasis to the lateral lymph nodes who refuse neo-
adjuvant therapy should be offered TME with lateral lymph 
node dissection. In our study, cancer cells were detected in 
some swollen lateral lymph nodes removed during operation 
and some of these lateral lymph nodes were stained. Despite 
Fig. 1 Gross specimen of rectal cancer removed under laparoscopy after injection of carbon nanoparticle suspension. The left shows the stained 
periphery which should be protected from damage during the operative procedures; the right shows the stained lymph node. The blue arrow 
indicates the interface of the resection; the yellow arrow indicates the dyed lymph node
Fig. 2 Histochemical appearance of the tumor tissues from a rectal cancer patient injected with carbon nanoparticle suspension. Tumor cells could 
be examined clearly under microscopy after being stained by hematoxylin and eosin, indicating that the carbon nanoparticles had no effect on the 
histochemical observation and diagnosis
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our study’s small sample size, performing lateral lymph node 
dissection on patients with mid-low rectal cancer and swol-
len lateral lymph nodes appeared to be efficacious. Accord-
ing to Fujita et al. [10], narrowing the scope of lateral lymph 
node dissection without neglecting the lymph nodes might 
be the best choice. Several lateral lymph nodes were stained 
after the submucous injection of carbon nanoparticle sus-
pensions. This technique enabled surgeons to remove more 
lateral lymph nodes without extending the scope of lateral 
lymph node dissection.
We did not found detailed reports about the adverse 
effects of the injection of carbon nanoparticle suspen-
sions on patients’ health. Carbon nanoparticle has not 
been reported to have mutagenicity or carcinogenesis 
as confirmed by van Tongeren et  al. [16]; meanwhile, 
Magrez et al. [17] had confirmed that carbon nanoparti-
cle showed no adverse influence on the central nervous 
system, cardiovascular system, or respiratory system.
Conclusions
Submucosal injection of carbon nanoparticle suspensions 
may improve the success rate of TME and make pathologic 
staging more accurate. Moreover, for selected patients, it 
may help surgeons narrow the scope of lateral lymph node 
dissection. Considering the limitations of our study, a larger-
scale study is needed to determine the effect of Submucosal 
injection of carbon nanoparticle suspensions on the opera-
tion outcomes in patients with mid-low rectal cancer.
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